Pan-tumor activity of olomorasib (LY3537982), a second-generation KRAS G12C inhibitor (G12Ci), in patients with KRAS G12C-mutant advanced solid tumors Meeting Abstract

  


Authors: Heist, R. S.; Koyama, T.; Murciano-Goroff, Y. R.; Hollebecque, A.; Cassier, P. A.; Han, J. Y.; Tosi, D.; Sacher, A. G.; Burns, T. F.; Spira, A. I.; Gomez-Roca, C. A.; Shimizu, T.; Ammakkanavar, N. R.; Sabari, J. K.; Nagasaka, M.; Fink, A. A.; Chen, A.; Willard, M. D.; Oxnard, G. R.; Kuboki, Y.
Abstract Title: Pan-tumor activity of olomorasib (LY3537982), a second-generation KRAS G12C inhibitor (G12Ci), in patients with KRAS G12C-mutant advanced solid tumors
Meeting Title: 2024 ASCO Annual Meeting
Journal Title: Journal of Clinical Oncology
Volume: 42
Issue: 16 Suppl.
Meeting Dates: 2024 May 31-Jun 4
Meeting Location: Chicago, IL
ISSN: 0732-183X
Publisher: American Society of Clinical Oncology  
Date Published: 2024-06-01
Language: English
ACCESSION: WOS:001275557400616
PROVIDER: wos
DOI: 10.1200/JCO.2024.42.16_suppl.3007
Notes: Meeting Abstract: 3007 -- Source: Wos
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Yonina Robbie Murciano-Goroff
    66 Murciano-Goroff
Related MSK Work